Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03288545
Other study ID # SGN22E-002
Secondary ID MK-3475-869KEYNO
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 11, 2017
Est. completion date December 31, 2026

Study information

Verified date October 2023
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.


Description:

This study will examine the safety and anticancer activity of enfortumab vedotin (EV) given intravenously as monotherapy and in combination with other anticancer therapies as first line (1L) and second line (2L) treatment for patients with urothelial cancer. The primary goal of the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone and in combination with pembrolizumab and/or chemotherapy. The study will be conducted in multiple parts: Locally advanced or metastatic urothelial cancer: - Dose escalation - Expansion - Part 1: Cohorts A and Optional B - Part 2: Cohorts D, E, and Optional F - Part 3: Cohort G. - Randomized Cohort K - EV Monotherapy Arm - EV Combination Arm Muscle invasive bladder cancer: - Cohort H - Optional Cohort J - Cohort L


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 348
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Locally advanced or metastatic urothelial cancer (la/mUC) - Cohorts A, B, D, E, F, G and K. - Histologically documented la/mUC, including squamous differentiation or mixed cell types. - An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2: Participants with ECOG performance status of 2 must meet the following additional criteria: hemoglobin =10 g/dL, GFR =50 mL/min, may not have NYHA Class III heart failure. - Eligible for pembrolizumab (Dose-escalation cohorts, Cohorts A, B, G and K Combination Arm). - Dose-escalation cohorts: Ineligible for first-line cisplatin-based chemotherapy and no prior treatment for la/mUC, or have disease progression following at least 1 platinum-containing treatment. - Cohort A: Ineligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort B: Must have disease progression during/following treatment with at least 1 platinum-containing regimen for la/mUC or disease recurrence. - Cohort D: Eligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort E: Ineligible for cisplatin-based chemotherapy, eligible for carboplatin, and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort F: Ineligible for platinum-based chemotherapy, or disease progression during/following at least 1 prior treatment for la/mUC. Eligible for gemcitabine. - Cohort G: Eligible for platinum-based chemotherapy (either cisplatin or carboplatin) and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. - Cohort K: Ineligible for cisplatin-based chemotherapy due to at least 1 of the following: Glomerular filtration rate (GFR) <60 mL/min and =30 mL/min, ECOG performance status of 2, NCI CTCAE Version 4.03 Grade =2 hearing loss, New York Heart Association (NYHA) Class III heart failure. No prior systemic treatment for locally advanced or metastatic disease. No adjuvant/neoadjuvant platinum-based therapy within 12 months prior to randomization. - Muscle Invasive Bladder Cancer (MIBC)- Cohorts H, J and L. - Histologically confirmed MIBC with predominant >50% urothelial histology: Cohorts H and J: Clinical stage cT2-T4aN0M0; Cohort L: Clinical stage cT2-T4aN0M0 or cT1-T4aN1M0: Participants with pT1 disease are eligible only if they have N1 disease on imaging. Mixed cell types are eligible if urothelial cancer is predominant (>50%); Participants with plasmacytoid and/or neuroendocrine tumors are ineligible regardless of component percentage. Urothelial tumors not originating in the bladder (eg, upper tract tumors, urethral tumors) are ineligible. - Must be cisplatin-ineligible. - Cohort-specific eligibility: Cohort J, H, and L: No prior systemic treatment, chemoradiation, or radiation therapy for MIBC. May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy for non-MIBC; Cohort J: Eligible for pembrolizumab. - ECOG performance status of 0, 1, or 2. - Anticipated life expectancy of =3 months. - Tumor samples with an associated pathology report from the diagnostic transurethral resection of a bladder tumor done 90 days prior to the first dose of study treatment must be available prior to enrollment and determined to be sufficient for pathology review and biomarker analysis. - Participants must be deemed eligible for RC+PLND. Exclusion Criteria: - la/mUC - Cohorts A, B, D, E, F, G, and K - Received any prior treatment with a PD-1 inhibitor, PD-L1 inhibitor, or PD-L2 inhibitor, except Cohort F. - Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, OX-40 agonists, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (except Cohort F). - Ongoing sensory or motor neuropathy Grade 2 or higher. - Active central nervous system (CNS) metastases. - Ongoing clinically significant toxicity (Grade 2 or greater) associated with prior treatment (including radiotherapy or surgery). - Conditions requiring high doses of steroids or other immunosuppressive medications. - Prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs). - Uncontrolled diabetes mellitus. - MIBC - Cohorts H, J, and L - Received prior systemic treatment, chemoradiation, and/or radiation therapy of muscle invasive bladder cancer. - Received any prior treatment with a CPI. - Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, CTLA-4 inhibitors, or OX-40 agonists. - For participants in Cohort H, evidence of nodal disease on imaging. For participants in Cohort L, =N2 nodal disease on imaging. - Participant has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC. - Ongoing sensory or motor neuropathy Grade 2 or higher. - Conditions requiring high doses of steroids or other immunosuppressive medications. - Prior treatment with enfortumab vedotin or other MMAE-based ADCs for urothelial cancer. - Participants with a history of another invasive malignancy within 3 years before first dose of study drug.

Study Design


Intervention

Drug:
enfortumab vedotin (EV)
Intravenous (IV) infusion on days 1 and 8 every 21 days
pembrolizumab
IV infusion on day 1 every 21 days
cisplatin
IV infusion on day 1 every 21 days
carboplatin
IV infusion on day 1 every 21 days
gemcitabine
IV infusion on days 1 and 8 every 21 days

Locations

Country Name City State
Canada Site CA11008 East Brampton Ontario
Canada Site CA11011 Kingston Ontario
Canada Site CA11005 Montreal Quebec
Canada Site CA11013 Montreal Quebec
Canada Site CA11002 Sherbrooke Quebec
Canada Site CA11001 Toronto Ontario
France Site FR33008 Bordeaux
France Site FR33005 Dijon
France Site FR33003 Lyon
France Site FR33004 Marseilles
France Site FR33010 Moselle
France Site FR33002 Nice Cedex
France Site FR33006 Pierre-Benite
France Site FR33001 Strasbourg
Italy Site IT39002 Terni
Puerto Rico Site PR78701 Rio Piedras
Spain Site ES34006 Barcelona
Spain Site ES34001 Madrid
Spain Site ES34008 Madrid
Spain Site ES34012 Madrid
Spain Site ES34007 Pamplona
Spain Site ES34005 Sabadell
Spain Site ES34004 Santander
United States New York Oncology Hematology, P.C. Albany New York
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States Alaska Urological Institute Anchorage Alaska
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Piedmont Cancer Institute Atlanta Georgia
United States Winship Cancer Institute / Emory University School of Medicine Atlanta Georgia
United States Rocky Mountain Cancer Centers - Aurora Aurora Colorado
United States University of Colorado Hospital / University of Colorado Aurora Colorado
United States Memorial Sloan Kettering Cancer Center - Basking Ridge Basking Ridge New Jersey
United States Tower Hematology Oncology Medical Group Beverly Hills California
United States Boca Raton Regional Hospital / Lynn Cancer Institute Boca Raton Florida
United States CMOH Broomall Broomall Pennsylvania
United States Roswell Park Cancer Institute Buffalo New York
United States Gabrail Cancer Center Research, LLC Canton Ohio
United States UNC Lineberger Comprehensive Cancer Center / University of North Carolina Chapel Hill North Carolina
United States Medical University of South Carolina/Hollings Cancer Center Charleston South Carolina
United States Levine Cancer Institute Charlotte North Carolina
United States University of Virginia Charlottesville Virginia
United States Sarah Cannon Research Institute Chattanooga Tennessee
United States University of Chicago Medical Center Chicago Illinois
United States Case Western Reserve University / University Hospitals Case Medical Center Cleveland Ohio
United States Memorial Sloan Kettering Cancer Center - Commack Commack New York
United States Decatur Memorial Hospital - Illinois Decatur Illinois
United States Northwestern Medicine Cancer Center - Kishwaukee / Kishwaukee Cancer Center DeKalb Illinois
United States Henry Ford Health System Detroit Michigan
United States Duke University Medical Center Durham North Carolina
United States Southcoast Centers for Cancer Care - Fairhaven Site Fairhaven Massachusetts
United States Highlands Oncology Group Fayetteville Arkansas
United States Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center Fort Lauderdale Florida
United States Texas Oncology - Fort Worth Cancer Center Fort Worth Texas
United States Northwestern Medicine Cancer Center Delnor Geneva Illinois
United States Banner MD Anderson Cancer Center Gilbert Arizona
United States Saint Francis Hospital Cancer Center Greenville South Carolina
United States Vidant Medical Center Greenville North Carolina
United States Hackensack University Medical Center Hackensack New Jersey
United States Memorial Sloan Kettering Cancer Center - Westchester Harrison New York
United States Penn State Milton S. Hershey Medical Center Hershey Pennsylvania
United States University of Mississippi Medical Center Jackson Mississippi
United States Mayo Clinic Florida Jacksonville Florida
United States UC San Diego / Moores Cancer Center La Jolla California
United States Northwell Cancer Center / Monter Cancer Center Lake Success New York
United States McLaren Greater Lansing Hospital Lansing Michigan
United States OptumCare Cancer Center Las Vegas Nevada
United States Nebraska Hematology Oncology P.C. Lincoln Nebraska
United States Cardinal Bernardin Cancer Center / Loyola University Medical Center Maywood Illinois
United States University of Miami Miami Florida
United States Memorial Sloan Kettering Cancer Center - Monmouth Middletown New Jersey
United States Medical College of Wisconsin (Milwaukee) Milwaukee Wisconsin
United States NYU Winthrop Hospital Mineola New York
United States University of Minnesota Minneapolis Minnesota
United States Memorial Sloan Kettering Cancer Center - Bergen Montvale New Jersey
United States Carolina Urologic Research Center Myrtle Beach South Carolina
United States Tennessee Oncology / Sarah Cannon Research Institute Nashville Tennessee
United States Yale Cancer Center New Haven Connecticut
United States Ochsner Clinic Foundation New Orleans Louisiana
United States Tulane University Hospital and Clinic New Orleans Louisiana
United States Memorial Sloan Kettering Cancer Center New York New York
United States New York University (NYU) Cancer Institute New York New York
United States Weill Cornell Medical College New York New York
United States Virginia Oncology Associates - Norfolk Norfolk Virginia
United States Eastern CT Hematology and Oncology Associates Norwich Connecticut
United States University of California Irvine - Newport Orange California
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Mayo Clinic Arizona Phoenix Arizona
United States Allegheny General Hospital Pittsburgh Pennsylvania
United States University of Rochester Medical Center Rochester New York
United States University of California, Davis Comprehensive Cancer Center Sacramento California
United States Washington University School of Medicine - Siteman Cancer Center Saint Louis Missouri
United States Utah Cancer Specialists Salt Lake City Utah
United States University of Texas Health Science Center at San Antonio San Antonio Texas
United States University of California at San Francisco San Francisco California
United States Saint Joseph Heritage Medical Group Santa Rosa California
United States Maryland Oncology Hematology, P.A. Silver Spring Maryland
United States Medical Oncology Associates Spokane Washington
United States Stanford Cancer Center / Blood & Marrow Transplant Program Stanford California
United States Toledo Clinic Cancer Center Toledo Ohio
United States Arizona Oncology Associates, PC - HOPE Tucson Arizona
United States Texas Oncology - Tyler Tyler Texas
United States Memorial Sloan Kettering Cancer Center - Nassau Uniondale New York
United States Northwestern Medicine Cancer Center - Warrenville / Central DuPage Hospital - Cancer Care Warrenville Illinois
United States Georgetown University Medical Center Washington District of Columbia
United States University of Kansas Cancer Center Westwood Kansas
United States Kaiser Permanente Southern California Woodland Hills California

Sponsors (3)

Lead Sponsor Collaborator
Astellas Pharma Global Development, Inc. Merck Sharp & Dohme LLC, Seagen Inc.

Countries where clinical trial is conducted

United States,  Canada,  France,  Italy,  Puerto Rico,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only) Descriptive statistics will be used to summarize results. Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Primary Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only) Descriptive statistics will be used to summarize results. Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Primary Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only) The proportion of patients with confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 Up to 3 years
Primary Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only) The proportion of patients with absence of viable tumor tissue at the time of radical cystectomy. Up to approximately 5 months
Secondary Incidence of dose-limiting toxicity (DLT) Incidence of DLTs (dose-escalation expansion Cohorts D, E, F, and the first 6 patients of Cohort G). 21 days
Secondary Confirmed ORR by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) The proportion of patients with confirmed CR or PR according to RECIST 1.1. Up to 3 years
Secondary Confirmed ORR by BICR according to RECIST 1.1 (Dose escalation and Cohort A only) The proportion of patients with confirmed CR or PR according to RECIST 1.1 Up to 3 years
Secondary Confirmed ORR by investigator assessment per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only) The proportion of patients with confirmed CR or PR according to iRECIST. Up to 3 years
Secondary Disease control rate (DCR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) Proportion of patients with CR, PR, or stable disease (SD) according to RECIST 1.1. Up to 5 years
Secondary DCR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only) Proportion of patients with CR, PR, or stable disease (SD) according to RECIST 1.1 Up to 3 years
Secondary DCR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts using pembrolizumab only) Proportion of patients with CR, PR, or SD according to iRECIST. Up to 3 years
Secondary Duration of response (DOR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD per RECIST 1.1) or to death due to any cause, whichever comes first. Up to 5 years
Secondary DOR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only) The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD per RECIST 1.1 or to death due to any cause, whichever comes first Up to 5 years
Secondary DOR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only) The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD per iRECIST or to death due to any cause, whichever comes first. Up to 5 years
Secondary Progression free survival on study therapy (PFS) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only) The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1) on or following study therapy, or to death due to any cause, whichever comes first. Up to 5 years
Secondary PFS by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only) The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1) on or following study therapy, or to death due to any cause, whichever comes first Up to 5 years
Secondary PFS by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only) The time from start of study treatment to first documentation of objective tumor progression (PD per iRECIST) on or following study therapy, or to death due to any cause, whichever comes first. Up to 5 years
Secondary Event-free (EFS) on study therapy by BICR (Cohort L only) The time from the start of study treatment to the first occurrence of any of the following events: (1) Radiographic disease progression precluding a curative intent surgery as assessed by BICR prior to RC+PLND. (2) Failure to undergo RC+PLND for participants with residual muscle-invasive disease and/or any radiographic disease present. (3) Gross residual disease left behind at time of RC+PLND. (4) Local or distant recurrence post-RC as assessed by CT or MRI and/or biopsy. (5) Death from any cause. Up to 3 years
Secondary Event-free (EFS) on study therapy by investigator assessment (MIBC cohorts only) The time from the start of study treatment to the first occurrence of any of the following events: (1) Radiographic disease progression precluding a curative intent surgery as assessed by BICR prior to RC+PLND. (2) Failure to undergo RC+PLND for participants with residual muscle-invasive disease and/or any radiographic disease present. (3) Gross residual disease left behind at time of RC+PLND. (4) Local or distant recurrence post-RC as assessed by CT or MRI and/or biopsy. (5) Death from any cause. Up to 3 years
Secondary Overall survival (OS) (all cohorts) The time from start of study treatment to date of death due to any cause. Up to 5 years
Secondary Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Cmax will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for monomethyl auristatin E (MMAE): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Cmax will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for total antibody (Tab): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Cmax will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Blood samples for ATA analysis will be collected. Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Secondary PK parameter for enfortumab vedotin: Time to maximum concentration (Tmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Tmax will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Tmax will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for Tab: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) Tmax will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for enfortumab vedotin: Area under the concentration-time curve (AUC) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) AUC will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for MMAE: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) AUC will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary PK parameter for Tab: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only) AUC will be derived from the PK blood samples collected. Through 2 cycles of treatment, up to 42 days
Secondary Pathologic downstaging (pDS) rate by central pathology review (MIBC cohorts only) The pDS rate is defined as patients with tumors Up to approximately 5 months
Secondary Disease-free survival (DFS) by investigator assessment (MIBC cohorts only) DFS is defined as the time from RC to the time of first occurrence of a DFS event, including local recurrence of urothelial cancer (UC), urinary tract recurrence of UC, distant metastasis of UC, or death from any cause. Up to approximately 5 years
Secondary DFS by BICR (Cohort L only) DFS is defined as the time from RC to the time of first occurrence of a DFS event Up to 3 years
Secondary Type, incidence, severity, seriousness, and relatedness of AEs (Randomized Cohort K and MIBC cohorts only) Descriptive statistics will be used to summarize results. Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years
Secondary Type, incidence, and severity of laboratory abnormalities (Randomized Cohort K and MIBC cohorts only) Descriptive statistics will be used to summarize results. Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years
Secondary Percentage of planned radical cystectomy and pelvic lymph node dissections (RC+PLND) delayed due to treatment-related AEs (MIBC cohorts only) Delayed is defined as greater than 12 weeks after the last dose of treatment. Up to approximately 5 months
See also
  Status Clinical Trial Phase
Terminated NCT02612194 - LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Phase 2
Active, not recruiting NCT02805608 - uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer Phase 2
Not yet recruiting NCT02534623 - Postoperative Quality of Recovery After Transurethral Resection of the Bladder N/A
Recruiting NCT02228473 - Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort N/A
Completed NCT02778243 - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level N/A
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Terminated NCT02560038 - Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer Phase 2
Not yet recruiting NCT02252445 - Propofol and Sevoflurane for Catheter-Related Bladder Discomfort N/A
Not yet recruiting NCT02760953 - TURBt With Adjuvant Cryoablation to Treat Bladder Cancer N/A
Terminated NCT04430036 - AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Phase 2
Active, not recruiting NCT06289283 - Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT03404791 - A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy Phase 1
Terminated NCT01479348 - Imaging Study for FdCyd and THU Cancer Treatment Early Phase 1
Recruiting NCT05742867 - A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
Recruiting NCT03973671 - Prospective Sample Collection for Cancer of Bladder